<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Topical tretinoin (topical all-trans retinoic acid): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Topical tretinoin (topical all-trans retinoic acid): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Topical tretinoin (topical all-trans retinoic acid): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10014" href="/d/html/10014.html" rel="external">see "Topical tretinoin (topical all-trans retinoic acid): Drug information"</a> and <a class="drug drug_patient" data-topicid="11118" href="/d/html/11118.html" rel="external">see "Topical tretinoin (topical all-trans retinoic acid): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F230490"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Altreno;</li>
<li>Atralin;</li>
<li>Avita [DSC];</li>
<li>Refissa [DSC];</li>
<li>Renova;</li>
<li>Renova Pump;</li>
<li>Retin-A;</li>
<li>Retin-A Micro;</li>
<li>Retin-A Micro Pump</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868494"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Retin-A;</li>
<li>Retin-A Micro;</li>
<li>Stieva-A</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050424"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Acne Products</span>;</li>
<li>
<span class="list-set-name">Retinoic Acid Derivative</span>;</li>
<li>
<span class="list-set-name">Vitamin, Topical</span></li></ul></div>
<div class="block dop drugH1Div" id="F230501"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b> Children ≥8 years and Adolescents: Topical: Apply to affected areas once daily. Begin therapy with a weaker formulation of tretinoin and increase the concentration as tolerated; if stinging or irritation develop, decrease frequency of application. Approved ages varies by product; see individual product labeling. Guidelines suggest that topical retinoids may be used as part of a therapeutic regimen for all types and severity of acne in children and adolescents; however, specific data for each tretinoin product formulation may not be available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Product specific:</p>
<p style="text-indent:-2em;margin-left:6em;">Altreno (Lotion 0.05%): Children ≥9 years and Adolescents: Topical: Apply to affected areas once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Atralin (Gel 0.05%): Children ≥10 years and Adolescents: Topical: Apply once daily to acne lesions before bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">Retin-A (Cream 0.025%, 0.05%, or 0.1%; Gel 0.01% or 0.025%), Tretin-X (Cream 0.025%, 0.0375%, 0.05%, 0.075%, or 0.1%): Children ≥12 years and Adolescents: Topical: Apply once daily to acne lesions before bedtime or in the evening.</p>
<p style="text-indent:-2em;margin-left:6em;">Retin-A Micro:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 8 to &lt;12 years: Limited data available: Gel (0.04%): Topical: Apply once daily to acne lesions before bedtime or in the evening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20498178','lexi-content-ref-22712470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20498178','lexi-content-ref-22712470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Gel (0.04%, 0.06%, 0.08%, or 0.1%): Topical: Apply once daily to acne lesions before bedtime or in the evening.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192987"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however dosage adjustment unlikely needed due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51192988"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however dosage adjustment unlikely needed due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F230493"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10014" href="/d/html/10014.html" rel="external">see "Topical tretinoin (topical all-trans retinoic acid): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b>
<b>Topical:</b> Apply to acne lesions once daily before bedtime or in the evening. Consider starting with the lowest possible concentration to minimize skin irritation and increase potency as tolerated. For moderate to severe acne, may be used as part of an appropriate combination regimen. Avoid simultaneous application with benzoyl peroxide (may reduce tretinoin efficacy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Graber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Graber.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82288927-2829-4b33-8135-aedccc70914d">Palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Palliation of fine wrinkles (Refissa/Renova), mottled hyperpigmentation, and tactile roughness of facial skin (Refissa):</b>
<b>Topical:</b> Apply a pea-sized amount of cream to entire face once daily in the evening or before bedtime.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991783"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988957"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F230465"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stinging of the skin (21%), local dryness (4% to 16%), hypopigmentation (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site erythema (2% to 51%), application site irritation (1% to 50%; severe: ≤3%), local skin exfoliation (1% to 49%), application site pruritus (2% to 35%), application site burning (8% to 30%), local desquamation (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperpigmentation (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site dermatitis (4%), application site pain (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Dermatologic: Skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Contact dermatitis, skin changes (atypical changes in melanocytes and keratinocytes, increased dermal elastosis; treatment lasting &gt;48 weeks)</p></div>
<div class="block coi drugH1Div" id="F230477"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to tretinoin or any component of the formulation. <b>Note:</b> There are no contraindications listed in Altreno, Atralin, or Retin-A Micro US labeling.</p></div>
<div class="block war drugH1Div" id="F230462"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fish allergies: Atralin gel contains soluble fish proteins; use caution in patients with sensitivities or allergies to fish.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Discontinue tretinoin if drug sensitivity, chemical irritation, or a systemic adverse reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Use is associated with increased susceptibility/sensitivity to UV light; avoid or minimize excessive exposure to sunlamps or sunlight. Daily sunscreen (SPF ≥15) use and other protective measures (eg, clothing over treated areas) are recommended. Use with caution in patients with personal or family history of skin cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin irritation: Treatment can increase skin sensitivity to weather extremes of wind or cold. Excessive dryness, redness, and swollen or blistered skin may occur. Also, concomitant topical medications (eg, medicated or abrasive soaps, cleansers, or cosmetics with a strong drying effect) should be used with caution due to increased skin irritation. Depending on the severity of irritation, use a moisturizer, reduce the amount or frequency, or discontinue use until irritation disappears.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Eczema: Use with caution in patients with eczema; may cause severe irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cream 0.02%: Do not use the 0.02% cream for longer than 52 weeks when using for palliation of fine wrinkles.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cream 0.05%: Do not use the 0.05% cream for longer than 48 weeks when using for palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gel and Stieva-A cream [Canadian product]: Flammable; do not expose to high temperatures or flame.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only; avoid contact with abraded skin, sunburned skin, mucous membranes, eyes, mouth, angles of the nose. When used for palliation of fine wrinkles, mottled hyperpigmentation, or facial skin roughness, should be used as part of a comprehensive skin care and sun avoidance program.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878657"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F230472"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avita: 0.025% (20 g [DSC], 45 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Refissa: 0.05% (20 g [DSC], 40 g [DSC]) [contains edetate (edta) disodium, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renova: 0.02% (20 g, 40 g, 60 g) [contains benzyl alcohol, cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renova Pump: 0.02% (44 g) [contains benzyl alcohol, cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A: 0.025% (20 g, 45 g); 0.05% (20 g, 45 g); 0.1% (20 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025% (20 g, 45 g); 0.05% (20 g, 40 g [DSC], 45 g); 0.1% (20 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atralin: 0.05% (45 g) [contains benzyl alcohol, butylparaben, ethylparaben, fish collagen hydrolyzates, isobutylparaben, methylparaben, propylparaben, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avita: 0.025% (20 g [DSC], 45 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A: 0.01% (15 g, 45 g); 0.025% (15 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A Micro: 0.04% (20 g, 45 g); 0.1% (20 g, 45 g) [contains benzyl alcohol, disodium edta, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A Micro Pump: 0.04% (50 g) [contains benzyl alcohol, disodium edta, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A Micro Pump: 0.06% (50 g) [contains benzyl alcohol, edetate (edta) disodium, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A Micro Pump: 0.08% (50 g); 0.1% (50 g) [contains benzyl alcohol, disodium edta, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.01% (15 g, 45 g); 0.025% (15 g, 45 g); 0.04% (20 g, 45 g, 50 g); 0.05% (45 g); 0.08% (50 g); 0.1% (20 g, 45 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Altreno: 0.05% (20 g, 45 g) [contains benzyl alcohol, methylparaben, trolamine (triethanolamine)]</p></div>
<div class="block geq drugH1Div" id="F230458"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F230479"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Renova External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.02% (per gram): $7.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Renova Pump External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.02% (per gram): $7.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Retin-A External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $0.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $0.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $1.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Tretinoin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $5.02 - $6.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $5.63 - $7.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $6.57 - $8.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Atralin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $15.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Retin-A External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per gram): $1.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $1.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Retin-A Micro External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.04% (per gram): $26.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $26.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Retin-A Micro Pump External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.04% (per gram): $21.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.06% (per gram): $21.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.08% (per gram): $21.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $21.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Tretinoin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per gram): $5.32 - $6.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $5.36 - $6.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $7.50 - $9.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Tretinoin Microsphere External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.04% (per gram): $15.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.08% (per gram): $19.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $15.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Altreno External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $3.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868495"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A: 0.01% ([DSC]); 0.025% ([DSC]); 0.05% (30 g); 0.1% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.01% (25 g); 0.025% ([DSC]); 0.05% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A: 0.01% ([DSC]); 0.025% (30 g) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retin-A Micro: 0.04% (20 g, 45 g, 50 g); 0.1% (2 g, 20 g, 45 g, 50 g) [contains benzyl alcohol, disodium edta, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.01% (25 g); 0.025% (25 g); 0.05% (25 g)</p></div>
<div class="block admp drugH1Div" id="F52613964"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Topical: For external use only; not for oral, ophthalmic, or intravaginal use. Prior to application, wash hands; gently wash face with a mild soap; pat dry and wait 20 to 30 minutes. Apply thin layer to affected area in the evening or before bedtime, avoiding eyes, mouth, paranasal creases, and mucous membranes. If stinging or irritation develop, temporarily discontinue or decrease frequency of application. Wash hands immediately after applying. Avoid use of products to the affected area that contain high concentrations of alcohol, astringents, or spices. Do not apply to sunburned skin. If combination topical therapy is required, consider separating applications (eg, one drug in the morning and the other in the evening or before bedtime).</p>
<p style="text-indent:-2em;margin-left:4em;">Retin-A Micro: Avoid contact with lime peel and application area.</p></div>
<div class="block adm drugH1Div" id="F230474"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For topical external use only; not for oral, ophthalmic, or intravaginal use. Prior to application, wash hands; gently wash face with a mild soap; pat dry and wait 20 to 30 minutes. Apply thin layer to affected area in the evening or before bedtime, avoiding eyes, ears, nostrils, and mouth. If stinging or irritation develop, temporarily discontinue or decrease frequency of application. Wash hands immediately after applying. Avoid use of products to the affected area that contain high concentrations of alcohol, astringents, or spices. Do not apply to sunburned skin. If combination topical therapy is required, consider separating applications (eg, one drug in the morning and the other in the evening or before bedtime).</p>
<p style="text-indent:-2em;margin-left:2em;">Retin-A Micro: Avoid contact with lime peel and application area.</p></div>
<div class="block hazard drugH1Div" id="F49132672"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal (NIOSH 2016). Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F230485"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Altreno lotion, Atralin gel, Avita gel: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from freezing.</p>
<p style="text-indent:-2em;margin-left:2em;">Avita cream: Store below 30°C (86°F). Avoid freezing.</p>
<p style="text-indent:-2em;margin-left:2em;">Refissa: Store at 20°C to 25°C (68°F to 77°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">Renova: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Retin-A cream, Tretin-X cream: Store below 27°C (80°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Retin-A gel: Store below 30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Retin-A Micro gel: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Store pump upright.</p>
<p style="text-indent:-2em;margin-left:2em;">Stieva-A [Canadian product]: Store at 15°C and 30°C (59°F and 86°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin A Acid [Canadian product]: Store at 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F53569305"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Topical treatment of acne vulgaris (Altreno: FDA approved in ages ≥9 years and adults; Atralin: FDA approved in ages ≥10 years and adults; Retin-A, Retin-A Micro, Tretin-X: FDA approved in ages ≥12 years and adults; Avita: FDA approved in adults); adjunctive treatment for mitigation (palliation) of fine wrinkles in patients who use comprehensive skin care and sun avoidance programs (Renova: FDA approved in adults); adjunctive treatment for mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and facial skin roughness in patients who do not achieve such palliation using comprehensive skin care and sun avoidance programs alone (Refissa: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F230514"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tretinoin may be confused with ISOtretinoin, Tenormin, triamcinolone, trientine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Renova [U.S., Canada] may be confused with Remov brand name for nimesulide [Italy]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F230502"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F230467"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F230486"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Vitamin A toxicity may rarely occur. Management: Avoid excessive intake of vitamin A (cod liver oil, halibut fish oil). </p></div>
<div class="block rep_considerations drugH1Div" id="F54231560"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">These products should not be used in women who are attempting to conceive or at high risk for pregnancy.</p></div>
<div class="block pri drugH1Div" id="F230480"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in some animal reproduction studies following topical application of tretinoin. Teratogenic effects were also observed in pregnant women following topical use; however, a causal association has not been established.</p>
<p style="text-indent:0em;margin-top:2em;">When treatment for acne is needed during pregnancy, other agents are preferred (Chien 2016; Kong 2013; Leachman 2006). These products should not be used in women who are pregnant.</p></div>
<div class="block pha drugH1Div" id="F230461"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tretinoin is a derivative of vitamin A. When used topically, it modifies epithelial growth and differentiation. In patients with acne, it decreases the cohesiveness of follicular epithelial cells and decreases microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.</p></div>
<div class="block phk drugH1Div" id="F230476"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Acne: ≥2 weeks, may take ≥7 weeks; Facial wrinkles: Up to 6 months</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Minimal</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Avita cream and gel: &lt;0.3%; Retin A Micro 0.1% gel: ~1%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; forms metabolites</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F230481"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">A Ret | Acretin | Airol | Eudyna | Optimal | Retin a</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">A-acido | A-acido emoliente | A-acido vital | Acudyne | Dorpiel | Neotretin | Niterey | Retacnyl | Reti skin | Reticne | Retin a | Vitanol a</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eudyna | Retin a</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Retin a | Retrieve | Stieva a</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alten | Cosmotrin | Nilac | Retin a | Trena | Trinon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kefrane | Retinova</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Effederm | Locacid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Acnederm | Retin a</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Retacnyl | Retin a | Retinova | Tretinoina | Vitacid | Vitanol a | Vitpeel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Retin a</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dermodan | Retacnyl | Retin a | Stieva a</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Wei te ming</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido retinoico | Acnicrem | Aldoquin anti-acne | Alquin-gel | Anti-acne | Betarretin | Eudyna | Retacnyl | Reticrem | Retigel | Retin a | Stieva a | Tersaderm ii</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Airol | Locacid | Retin a</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Airol | Cordes vas | Epi-aberel | Eudyna</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Arretin | Retacnyl | Retiderm | Retin a | Retinic | Retirides | Stieva a</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betarretin | Retacnyl | Retin a</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Airol | Ketrel | Retin a | Retirides</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acne-free | Acnetin A | Acretin | Eudyna | Locatret | Retin a</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Retinova | Retirides</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Avulga</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Avitcid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aberel | Effederm | Kerlocal | Ketrel | Locacid | Retacnyl | Retin a | Retinova | Retitop | Tretinoine Dci | Tretinoine kefrane</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acticin | Retin a</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Airol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Acta | Ketrel | Quali-A | Retacnyl | Retin a | Retrieve | Stieva a | T3 Actin | Trevit a | Vitacid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Eudyna | Facenol | Jeraklin | Melavita | Niotinex | Nuface | Reticor | Retin a | Tracne | Trentin | Vitacid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Retin a | Retinova | Retirides</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Airol | Locacid | Retavit | Retin a</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">A Ret | Adit | Airol | Aritop | Atret | Comedolytic | Eudyna | Mytret | Nexret | Nexret t | Nioret Nanogel | Retino a | Reto | Retop-a | Revize | Supatret | T nac | Trebor | Tret | Tretin | Trewor | Tronin | Xylem A</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Acne off</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Airol | Retin a | Tretinoina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Acnelin | Acretin | Airol | Optimal | Retin a | Smooderm</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Olcenon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acnesol | Axcel sorfic | Optimal | Retin a | Uniacne</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ajina | Date film | Enova a | Eudyna | Huons A | Minkle | Prosome A | Recknoin | Retacnyl | Retin a | Stieva a | Tretin | Two&amp;t</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Acretin | Airol | Eudyna | Retacnyl | Retin a | Smooderm</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">A Ret | Airol | Effederm | Ketrel | Locacid | Retacnyl | Retin a | Retinomycin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Airol | Aknoten | Cordes vas | Derugin | Eudyna | Retin a</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Locacid | Retinova | Tretinoine kefrane</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Airol | Aknoten | Derugin | Eudyna | Retin a</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Locacid | Retacnyl | Retisol-a</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ac.retinoic gi | Acfen-a | Acido retinoico | Airol | Arretin | Biovitol C | Eudyna | Retacnyl | Retin a | Stieva a | Tinitrend | Tretinoina | Xinbrotec | Yebemo</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">A Ret | Alten | Elra | Renova | Retacnyl | Retin a | Sorfic | Stieva a</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Acid a vit | Tretinoinum</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aberela | Cordes vas | Retirides</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Retin a | Retinova | Retrieve | Stieva a</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betarretin | Neotetrin | Retacnyl | Retin a | Stieva a | Tretinoina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acnoin t | Airol | Derm a | Extraderm | Retacnyl | Retin a | Stieva a | T3 Actin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Airol | Crometin-A | Ginza | Retin a | Tracnesan | Tretinex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Airol | Aknoten | Arretin ICN | Derugin | Locacid | Retin a</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Altinac | Altreno | Atralin | Avita | Renova | Retin a | Retin a micro | Tretin x | Tretinoin gel microsphere</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ketrel | Locacid | Retin a</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acnecur | Neotretin d | Neotretin m | Retacnyl | Stieva a</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Acne-Free | Acretin | Optimal | Retin-A | Smooderm</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acnelyse | Airol | Retin a</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Retin a</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Acne top | Acnelin | Acretin | Airol | Avotin A | Optimal | Retacnyl | Retin a | Smooderm</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aberela | Retinova</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Acta | Alten | Retacnyl | Retin a | Retinova | Stieva a | Trevit a</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Airol | Locacid | Retin a</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A-tinic | Acnetin A | Acvit a | Airol | Eudyna | Renova | Retacnyl | Retin a | Stieva a | Tina A</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aberel | Locacid | Retin a | Retisol-a</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acnelyse | Retino | Retino forte | Tre</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">080 antismallpox | A.a | Abet | Acne | Acned | Airful | Airol | Avo | Bolover | Derma lightening | Eudyna | Facely | Funoin | Relief | Retacnyl | Retin a</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Altreno | Retin a</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Acne free cream | Acnesol | Optimal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">A-acido | Acido vital | Airol | Betarretin | Neotretin | Retacnyl | Stieva a</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adina | Betarretin | Retacnyl | Retinei | Stieva a | Tretinax | Vitacid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Airol | Ilotycin a | Renova | Retacnyl | Retin a</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Acnesol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Altreno.1">
<a name="Altreno.1"></a>Altreno (tretinoin) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29298085">
<a name="29298085"></a>Anderson PO. Topical drugs in nursing mothers. <i>Breastfeed Med</i>. 2018;13(1):5-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/29298085/pubmed" id="29298085" target="_blank">29298085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atralin.1">
<a name="Atralin.1"></a>Atralin gel (tretinoin) [prescribing information]. Bridgewater, NJ: Coria Laboratories; August 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atralin.1">
<a name="Atralin.1"></a>Atralin gel (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avita.1">
<a name="Avita.1"></a>Avita (tretinoin) cream [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avita.1">
<a name="Avita.1"></a>Avita (tretinoin) gel [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26957383">
<a name="26957383"></a>Chien AL, Qi J, Rainer B, Sachs DL, Helfrich YR. Treatment of acne in pregnancy. <i>J Am Board Fam Med</i>. 2016;29(2):254-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/26957383/pubmed" id="26957383" target="_blank">26957383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22712470">
<a name="22712470"></a>Eichenfield LF, Hebert AA, Schachner L, Paller AS, Rossi AB, Lucky AW. Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study. <i>Pediatr Dermatol</i>. 2012;29(5):598-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/22712470/pubmed" id="22712470" target="_blank">22712470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. American Acne and Rosacea Society. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131 Suppl 3:S163-86. doi: 10.1542/peds.2013-0490B.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20498178">
<a name="20498178"></a>Eichenfield LF, Matiz C, Funk A, Dill SW. Study of the efficacy and tolerability of 0.04% tretinoin microsphere gel for preadolescent acne. <i>Pediatrics</i>. 2010;125(6):e1316-1323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/20498178/pubmed" id="20498178" target="_blank">20498178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.1">
<a name="Graber.1"></a>Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23657872">
<a name="23657872"></a>Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-87. doi: 10.1007/s40265-013-0060-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/23657872/pubmed" id="23657872" target="_blank">23657872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25255817">
<a name="25255817"></a>Korgavkar K, Wang F. Stretch marks during pregnancy: a review of topical prevention. <i>Br J Dermatol</i>. 2015;172(3):606-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/25255817/pubmed" id="25255817" target="_blank">25255817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.2012">
<a name="NIOSH.2012"></a>National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at <a href="https://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf" target="_blank">http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf</a>. Accessed January 21, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Refissa.1">
<a name="Refissa.1"></a>Refissa cream (tretinoin topical) [prescribing information]. San Antonio, TX: DPT Laboratories; November 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renova.1">
<a name="Renova.1"></a>Renova cream (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renova.2">
<a name="Renova.2"></a>Renova cream (tretinoin) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retin-A.1">
<a name="Retin-A.1"></a>Retin-A (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retin-A.2">
<a name="Retin-A.2"></a>Retin-A cream, gel (tretinoin) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retin-A.3">
<a name="Retin-A.3"></a>Retin-A Micro (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; January 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retin-A.4">
<a name="Retin-A.4"></a>Retin-A Micro (tretinoin) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; March 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retin-A.5">
<a name="Retin-A.5"></a>Retin-A Micro gel (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retin-A.6">
<a name="Retin-A.6"></a>Retin-A Micro gel (tretinoin) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stieva-A.1">
<a name="Stieva-A.1"></a>Stieva-A (tretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tretin-X.1">
<a name="Tretin-X.1"></a>Tretin-X (tretinoin) [prescribing information]. Cumberland, RI: Onset Dermatologics; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tretin-X.2">
<a name="Tretin-X.2"></a>Tretin-X cream (tretinoin) [prescribing information]. Cumberland, RI: Onset Dermatologies, LLC; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.2016">
<a name="NIOSH.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Vitamin A Acid (tretinoin) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1831256">
<a name="1831256"></a>Winston MH, Shalita AR, “Acne Vulgaris, Pathogenesis and Treatment,” <i>Pediatr Clin North Am</i>, 1991, 38(4):889-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/1831256/pubmed" id="1831256" target="_blank">1831256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12007012">
<a name="12007012"></a>Zip C. Common sense dermatological drug suggestions for women who are breast-feeding. <i>Skin Therapy Lett</i>. 2002;7(3):5-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/topical-tretinoin-topical-all-trans-retinoic-acid-pediatric-drug-information/abstract-text/12007012/pubmed" id="12007012" target="_blank">12007012</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12857 Version 511.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
